Investors

Investors

Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 28 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.9 billion (IQVIA, February 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio
CFO

Recent News

Teligent Secures Critical Supply during Canadian National Drug Crisis despite Worldwide Shortage

TORONTO , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ:TLGT) (“Teligent”), a specialty generic pharmaceutic...

Learn More

Teligent, Inc. Announces Second Quarter 2018 Results

BUENA, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. to Hold Conference Call for Second Quarter 2018 Results

BUENA, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More
See All News

Stock Information

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.


Full Quote

Events

More

Investor Overview